l-dos47
Small moleculeexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2012 (NCT02340208)
Timeline
Indications
Mechanism of action
- CEACAM6BINDING AGENT
binding agent - CEACAM6
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594480 ↗
Also known as
- l-dos47
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04203641 | Phase 1/Phase 2 (Phase 2) | Dec 11, 2019 | Helix BioPharma Corporation, HonorHealth Research Institute, Theradex |
| NCT03891173 | Phase 2 | Feb 19, 2019 | Europejskie Centrum Zdrowia Otwock, Helix BioPharma Corporation, KCR S.A. |
| NCT02309892 | Phase 1 | Apr 1, 2014 | Helix BioPharma Corporation, Theradex |
| NCT02340208 | Phase 1/Phase 2 (Phase 2) | May 1, 2012 | Helix BioPharma Corporation, Maria Sklodowska Curie Children's Hospital, Pharm-Olam International |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Helix BioPharma Corporation | For profit | 4 | 4 | 2 | 2012 |
| Theradex | For profit | 2 | 0 | 2 | 2014 |
| Europejskie Centrum Zdrowia Otwock | Academic/Hospital | 1 | 0 | 1 | 2019 |
| HonorHealth Research Institute | Academic/Hospital | 1 | 0 | 1 | 2019 |
| KCR S.A. | For profit | 1 | 0 | 1 | 2019 |
| Maria Sklodowska Curie Children's Hospital | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Pharm-Olam International | For profit | 1 | 0 | 1 | 2012 |
7 organizations
Page 1 / 1